1. GLP-1 Receptor Blockade Reduces Stimulated Insulin Secretion in Fasted Subjects With Low Circulating GLP-1
- Author
-
Sarah M Gray, Andrew L Hoselton, Radha Krishna, Cris A Slentz, and David A D’Alessio
- Subjects
Clinical Research Article ,Cross-Over Studies ,Dipeptidyl Peptidase 4 ,Endocrinology, Diabetes and Metabolism ,Sitagliptin Phosphate ,Biochemistry (medical) ,Clinical Biochemistry ,Fasting ,Arginine ,Biochemistry ,Glucagon-Like Peptide-1 Receptor ,Endocrinology ,Diabetes Mellitus, Type 2 ,Glucagon-Like Peptide 1 ,Insulin Secretion ,Humans ,Insulin - Abstract
Context Glucagon-like peptide 1 (GLP-1), an insulinotropic peptide released into the circulation from intestinal enteroendocrine cells, is considered a hormonal mediator of insulin secretion. However, the physiological actions of circulating GLP-1 have been questioned because of the short half-life of the active peptide. Moreover, there is mounting evidence for localized, intra-islet mediation of GLP-1 receptor (GLP-1r) signaling including a role for islet dipeptidyl-peptidase 4 (DPP4). Objective To determine whether GLP-1r signaling contributes to insulin secretion in the absence of enteral stimulation and increased plasma levels, and whether this is affected by DPP4. Methods Single-site study conducted at an academic medical center of 20 nondiabetic subjects and 13 subjects with type 2 diabetes. This was a crossover study in which subjects received either a DPP4 inhibitor (DPP4i; sitagliptin) or placebo on 2 separate days. On each day they received a bolus of intravenous (IV) arginine during sequential 60-minute infusions of the GLP-1r blocker exendin[9-39] (Ex-9) and saline. The main outcome measures were arginine-stimulated secretion of C-Peptide (C-PArg) and insulin (InsArg). Results Plasma GLP-1 remained at fasting levels throughout the experiments and IV arginine stimulated both α- and β-cell secretion in all subjects. Ex-9 infusion reduced C-PArg in both the diabetic and nondiabetic groups by ~14% (P Conclusion GLP-1r activation contributes to β-cell secretion in diabetic and nondiabetic people during α-cell activation, but in the absence of increased circulating GLP-1. These results are compatible with regulation of β-cells by paracrine signals from α-cells. This process may be affected by DPP4 inhibition.
- Published
- 2022
- Full Text
- View/download PDF